Breakthrough in cancer treatment: China approves PADCEV for advanced urothelial cancer
China's National Medical Products Administration (NMPA) has granted approval for PADCEV (enfortumab vedotin) to treat locally advanced or metastatic urothelial cancer (la/mUC) in adult patients. ... Read More